ARCH Venture Partners

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Kardigan is a pioneering heart health company dedicated to transforming cardiovascular drug development. It focuses on identifying and matching critical disease drivers with responsive patients from clinical trials, aiming to deliver curative medicines that go beyond symptom management, ultimately providing functional cures for cardiovascular diseases.

Rhygaze is a biotechnology company focused on developing innovative gene therapies aimed at restoring vision in individuals affected by blindness-related diseases. The company’s therapy utilizes advanced technology to deliver a light-sensor gene directly to cone cells that have lost their light sensitivity. By repairing these cells' ability to detect light, Rhygaze seeks to enable effective vision restoration for patients. Through its specialized approach, the company aims to make significant contributions to the healthcare industry and improve the quality of life for those facing vision loss.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Moleculent is a biotechnology company focused on advancing human health through technology-enabled products that utilize insights into the molecular basis of human biology. The company is dedicated to decoding human biology and aims to significantly enhance therapies and diagnostics by leveraging new scientific knowledge. Moleculent believes that a deeper understanding of molecular mechanisms, especially in relation to health and disease, will emerge over the next decade, paving the way for innovative healthcare solutions. Through its efforts, the company seeks to provide healthcare professionals with access to molecular science-based therapies and diagnostics that can improve patient care and outcomes.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Proniras Corporation is a preclinical-stage biotechnology company based in Seattle, Washington, focused on developing innovative parenteral medical countermeasure drugs, particularly tezampanel, for treating seizures and brain injuries. Founded in 2016, the company has demonstrated preclinical efficacy in addressing nerve agent-induced seizures, particularly in studies involving exposure to soman, a highly toxic chemical weapon. By targeting the central nervous system, Proniras aims to develop novel small-molecule therapeutics for various neurological conditions characterized by high unmet medical needs. Their research is designed to provide medical researchers with valuable tools for advancing treatments in this critical area.

Accompany Health provides comprehensive in-home primary care, including chronic illness management and treatment of new symptoms, and coordinates care across the full patient journey. The company offers at-home and virtual care, with round-the-clock support to address health needs any time, day or night. It focuses on cultivating long-term relationships with patients, ensuring consistent access to care and a stable point of contact year after year. Accompany Health serves individuals with complex needs, including low-income populations, helping them manage health journeys effectively and improve outcomes. By combining clinical delivery with technology-enabled care coordination, the company aims to reduce barriers such as waiting rooms and lines and to provide dignified care that supports patients throughout ongoing management of chronic conditions and new symptoms.

Basking Biosciences is developing a reversible thrombolytic therapy to restore blood flow to the brain during ischemic stroke, with the aim of preventing hemorrhage and long-term damage. The platform combines a primary agent that targets clot stability with a designed reversal agent that can be administered if bleeding occurs to neutralize the active compound and restore normal clotting, enabling treatment for acute ischemic stroke.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

UltraDx Bio is a biotechnology company that specializes in single-molecule digital high-sensitivity protein detection technology.

Magnet Biomedicine is a biotechnology company specializing in discovering novel molecular glues using its proprietary TrueGlue platform. This platform leverages advancements in human biology and proteomics to identify adhesives optimized for therapeutic effectiveness, enhancing selectivity and targeting previously challenging proteins across various disease areas such as cancer, cardiovascular disease, and immune disorders.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Bitterroot Bio specializes in developing innovative therapies for cardiovascular disease by harnessing the power of immunotherapy.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Paratus Sciences focuses on advancing human health and health security by studying the biology of bats. It integrates cell biology, genomics, informatics, and large-scale data inputs to compare disease resistance patterns in bats with those in humans, aiming to develop therapeutics that mimic bats' adaptations.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

Aera Therapeutics is a biotechnology company focused on advancing genetic medicines through its proprietary protein nanoparticle (PNP) delivery platform. This innovative platform utilizes endogenous human proteins derived from retroelements, which self-assemble into capsid-like structures capable of packaging and transferring nucleic acid cargo. By addressing the limitations of current delivery technologies, Aera aims to enhance the efficacy and reach of genetic therapies across various tissues and disease areas. Additionally, the company holds a licensed technology that features a therapeutic enzyme platform based on novel, compact, and programmable gene-editing enzymes, further expanding its capabilities in the field of genetic medicine.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

Akamis Bio is a clinical-stage oncology company dedicated to improving cancer patient outcomes through its innovative Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform. The company develops therapeutics that enable the immune system to recognize and clear solid tumors.

SonoThera is a biotechnology company focused on developing innovative genetic therapies using ultrasound technology. The company's mission is to create non-viral genetic medicines that address the root causes of human diseases. SonoThera specializes in ultrasound-guided nonviral gene therapy, aiming to provide effective treatments for conditions that currently have suboptimal or no available treatments. By leveraging this approach, SonoThera seeks to enhance the health and quality of life for millions of people worldwide.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Elephas is a company focused on revolutionizing cancer treatment through its innovative live tumor imaging diagnostics platform. By leveraging advances in cancer biology, multimodal microscopy, engineering, and artificial intelligence, Elephas aims to enhance clinical decision-making and personalize therapy for cancer patients. The company's approach involves the use of human live tumor fragments, allowing clinicians to determine the most effective treatment strategies for individual patients. In doing so, Elephas not only seeks to improve patient outcomes but also to expedite the drug development process, addressing the significant challenges faced in oncology.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Homeward delivers innovative rural health services for over 60 million Americans residing in rural communities. It employs multidisciplinary care teams offering both virtual and on-site care via mobile units, along with remote monitoring to enhance patient connections to high-quality, affordable healthcare.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Nutcracker Therapeutics is a biotechnology company based in Emeryville, California, that develops and manufactures mRNA therapeutics using a proprietary microfluidic, biochip-based platform. Its ACORN system is a computer-controlled RNA manufacturing platform that starts with a nucleic acid sequence and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated single-use biochips. The company provides a push-button mRNA synthesis and formulation capability, enabling fully integrated production of mRNA therapies at scale and on demand. The platform combines advances in RNA biology with manufacturing concepts inspired by semiconductors to enable rapid discovery, development, and manufacturing of complex mRNA therapies and vaccines. By offering on-demand production and a scalable capability, Nutcracker Therapeutics aims to support healthcare teams to produce multimodal therapeutics at the point of care.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Recuro Health is a developer of an integrated digital health platform that aims to transform the U.S. healthcare system from a reactive, disease-focused model to one centered on population health and outcomes. The company provides a tailored Digital Medical Home that caters to specific healthcare needs, offering essential virtual care services, including primary care, behavioral health, and urgent care. By equipping employers, providers, and managed care organizations with various digital tools, education, and guidance, Recuro Health enables patients to actively engage in their healthcare through health assessments and interactive communication with professionals, whether via messaging or video. This approach seeks to enhance patient involvement and improve health outcomes across diverse settings.

Slingshot Biosciences develops engineered synthetic cells to accelerate drug research and enable diagnostics and therapeutics. The company creates next-generation cellular tools that aim to simplify complex experiments, improve data standardization in cell analysis, and provide cost-effective solutions for research programs. Its work includes aligning cellular properties such as forward and side scatter of white blood cells to enable more consistent measurements and faster interpretation. By removing cold-chain barriers, Slingshot Biosciences seeks to broaden access to advanced diagnostics and therapeutics, supporting programs focused on neglected and rare diseases. Operating in the industrial synthetic biology space, the company concentrates on practical cellular technologies that can shorten development timelines and reduce costs for researchers.

ImmuneID is a precision immunology company that uses a proprietary platform to identify and therapeutically target millions of antibody interactions that drive immune diseases. The platform enables parallel, multiplexed, and unbiased analyses to develop therapeutics for autoimmunity, severe allergy, oncology, and infectious diseases, and helps researchers observe human immune responses throughout disease progression.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

ImmuneID is a precision immunology company that uses a proprietary platform to identify and therapeutically target millions of antibody interactions that drive immune diseases. The platform enables parallel, multiplexed, and unbiased analyses to develop therapeutics for autoimmunity, severe allergy, oncology, and infectious diseases, and helps researchers observe human immune responses throughout disease progression.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Altos Labs is a biotechnology company dedicated to cellular rejuvenation programming aimed at restoring cell health and resilience. The organization seeks to develop innovative approaches to medicine that can reverse diseases, injuries, and disabilities. By uniting a community of prominent scientists, clinicians, and industry leaders, Altos Labs fosters collaboration across its operations in the San Francisco Bay Area, San Diego, and Cambridge, UK, while also engaging in significant partnerships in Japan. Through its research and initiatives, the company aspires to transform the landscape of medical treatment.

Founded in San Diego, California in 2015, Encodia specializes in proteomics research. It develops scalable and parallelized approaches to protein analysis, aiming to accelerate novel disease treatments through personalized medicine.

Locanabio is a biotechnology company developing RNA-targeted gene therapies for underserved diseases, with a focus on neuromuscular, neurodegenerative, and retinal conditions. It employs an RNA-targeting platform to modify disease-causing RNA and correct aberrant transcripts, offering therapies distinct from DNA-based approaches. The company identifies target RNA sequences within transcripts and programs therapies to advance candidates for rare genetic neuromuscular, neurodegenerative, and retinal diseases. Located in San Diego, Locanabio aims to translate RNA-directed interventions into treatments for patients with severe conditions.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

Walden Biosciences, Inc. is a biotechnology company dedicated to developing innovative treatments for individuals suffering from kidney diseases, including chronic kidney disease and acute kidney injury. Founded in 2013 and based in Cambridge, Massachusetts, the company focuses on targeting specific biological mechanisms related to renal health. It specializes in therapies that address suPAR, an inflammatory biomarker linked to kidney function, and Dynamin, an enzyme crucial for maintaining podocyte integrity. By applying a systems-based approach, Walden Biosciences aims to transform the therapeutic landscape for kidney disease, offering targeted treatment options that address both rare and prevalent conditions affecting kidney health.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Nutcracker Therapeutics is a biotechnology company based in Emeryville, California, that develops and manufactures mRNA therapeutics using a proprietary microfluidic, biochip-based platform. Its ACORN system is a computer-controlled RNA manufacturing platform that starts with a nucleic acid sequence and produces optimized nanoparticle-encapsulated RNA therapeutics on dedicated single-use biochips. The company provides a push-button mRNA synthesis and formulation capability, enabling fully integrated production of mRNA therapies at scale and on demand. The platform combines advances in RNA biology with manufacturing concepts inspired by semiconductors to enable rapid discovery, development, and manufacturing of complex mRNA therapies and vaccines. By offering on-demand production and a scalable capability, Nutcracker Therapeutics aims to support healthcare teams to produce multimodal therapeutics at the point of care.

Singleron Biotechnologies Ltd. is a molecular diagnostic company specializing in single cell sequencing solutions. Founded in 2018 and based in Nanjing, China, with additional offices and laboratories in Suzhou, the United States, and Germany, the firm develops a range of innovative products, including the Singleron Matrix automated instrument for high-density microwell processing and GEXSCOPE single cell RNA sequencing kits. The company also offers a microfluidic chip for cell partitioning, magnetic beads for cell barcoding, and tools for data analysis such as CeleScope and SynEcoSys, which facilitate the interpretation of single cell sequencing data. Singleron provides services in single cell RNA sequencing, single nucleus RNA sequencing, and bioinformatics analysis, aiming to advance clinical diagnosis, drug development, and health management. The company collaborates with research institutes, hospitals, and pharmaceutical firms primarily in China and the United States, leveraging its exclusive IP license from Yale University to enhance its innovative capabilities in single cell analysis.

Bit.bio specializes in applying computational principles to biology, focusing on developing a scalable platform capable of producing consistent batches of every human cell. This enables more accurate research, drug discovery, and cell therapy applications.

JW Therapeutics (Shanghai) Co., Ltd. is a biotechnology company based in Shanghai, China, specializing in the development, transformation, and promotion of cell-based immunotherapies. The company focuses on innovative therapies that utilize chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to enhance the body's immune response against cancer. JW Therapeutics is dedicated to creating transformative treatments for both hematological cancers and solid tumors, with its lead product candidate being relmacabtagene autoleucel, a CAR-T therapy targeting anti-CD19. By advancing these groundbreaking therapies, JW Therapeutics aims to improve survival rates and quality of life for cancer patients.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

ROME Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative therapies for cancer and autoimmune diseases. Founded in 2019, the company utilizes the repeatome, which encompasses extensive segments of genetic material previously regarded as "junk DNA," to identify new drug targets and advance multiple discovery programs. ROME Therapeutics has assembled a team of experts in oncology, immunology, virology, and machine learning to drive its research and development efforts, aiming to harness this uncharted area of biology for effective treatments. Through its work, ROME seeks to provide healthcare professionals with powerful new options for addressing complex medical challenges.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

CERo Therapeutics is a biotechnology company focused on cellular immunotherapy and next-generation engineered T cell therapeutics for cancer. It develops platforms that integrate innate and adaptive immune programs to enhance anti-tumor activity and engage the body's full immune repertoire. The company was incorporated in 2016 and is headquartered in San Francisco, California. Its lead product, CER-1236, is an autologous T-cell therapy targeting a novel tumor antigen, TIM-4 ligand.

Vizgen develops next-generation spatially resolved transcriptomic profiling tools. Its patented MERFISH technology enables multiplexed single-molecule imaging of RNA species in individual cells, providing insights into biological systems and diseases across various applications such as oncology, immunology, neuroscience, and regenerative medicine.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.

Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Aspen Neuroscience develops autologous neuron replacement therapies based on induced pluripotent stem cells to treat neurological conditions, starting with Parkinson's disease. The company uses patient-specific restorative cell therapies by combining pluripotent stem cell biology with genomic approaches and artificial intelligence to address both sporadic and familial forms of Parkinson's disease, focusing on autologous neuron replacement to modify disease progression. Based in San Diego, California, the company is a development-stage biotechnology company pursuing expansion of its iPSC-based platform to other brain disorders.

Egenesis is a biotechnology company focused on gene editing and genome engineering to develop human-compatible organs, tissues, and cells for transplantation. Its platform enables the creation of solid organs and therapeutic cells intended for transplantation, addressing the global organ shortage. The company pursues programs in kidney and islet cell transplantation and related regenerative approaches. It is based in Cambridge, Massachusetts, with an additional office in New York.

Prime Medicine is a biotechnology company focused on developing genetic therapies using its innovative Prime Editing technology. This next-generation gene editing method allows for precise "search and replace" modifications in the genome, aimed at restoring normal genetic function. The company targets a wide range of diseases with significant unmet medical needs, leveraging the efficiency and versatility of its gene editing capabilities to address the underlying causes of these conditions. Through its commitment to advancing gene editing, Prime Medicine seeks to transform the landscape of genetic medicine.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

Encoded Therapeutics is a biotechnology company focused on precision gene therapies to treat a broad range of severe genetic disorders. It develops therapies and a platform that identifies human genome sequences that regulate gene expression using screening and computational approaches. The company's pipeline targets conditions across multiple pathways, including neurocircuitry, liver and metabolic disorders, neurodegeneration, and cardiovascular disease, aiming to help medical practitioners treat patients and improve outcomes. Based in South San Francisco, California, Encoded Therapeutics was founded in 2014 and was previously known as Encoded Genomics.

Ultivue develops multiplex biomarker assays for tissue phenotyping and digital pathology. Its products enable high-resolution fluorescent microscopy imaging, aiding life science research and potential clinical diagnostics.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Locanabio is a biotechnology company developing RNA-targeted gene therapies for underserved diseases, with a focus on neuromuscular, neurodegenerative, and retinal conditions. It employs an RNA-targeting platform to modify disease-causing RNA and correct aberrant transcripts, offering therapies distinct from DNA-based approaches. The company identifies target RNA sequences within transcripts and programs therapies to advance candidates for rare genetic neuromuscular, neurodegenerative, and retinal diseases. Located in San Diego, Locanabio aims to translate RNA-directed interventions into treatments for patients with severe conditions.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Maze Therapeutics is a biotechnology company focused on developing medicines that mimic the effects of rare, protective genetic variants to address unmet medical needs. Utilizing its Compass platform, the company identifies genetic variants associated with diseases and maps them to the biological pathways driving these conditions in specific patient populations.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

Vir Biotechnology, Inc. is a clinical-stage immunology company based in San Francisco, California, founded in 2016. It specializes in developing innovative therapeutic products aimed at treating and preventing serious infectious diseases. The company's pipeline includes several promising candidates, such as VIR-2218 and VIR-3434 for hepatitis B, VIR-2482 for influenza A, VIR-1111 for HIV, and VIR-2020 for tuberculosis. Vir Biotechnology employs advanced technologies and scientific expertise to manipulate immune responses and enhance pathogen-host interactions. The company has established various collaborations and agreements with notable organizations, including the Bill & Melinda Gates Foundation, National Institutes of Health, and Alnylam Pharmaceuticals, among others. Additionally, it has a manufacturing agreement with Samsung Biologics for the production of SARS-CoV-2 antibodies aimed at potential COVID-19 treatment. Through its innovative approaches, Vir Biotechnology aspires to significantly reduce the burden of infectious diseases in the future.

Geneception is a company focused on the development of breakthrough in gene and cell therapies that are fully-integrated.

Lyell Immunopharma Inc is a clinical-stage cell therapy company focused on developing innovative treatments for patients with solid tumors through T cell reprogramming. The company aims to overcome significant challenges in adoptive T cell therapy, specifically T cell exhaustion and loss of durable stemness, which impede effective and lasting responses in cancer treatment. Utilizing its proprietary platforms, Gen-R and Epi-R, Lyell is working to enhance the proliferative capacity, self-renewal, and differentiation abilities of T cells. The company's product pipeline includes several candidates, such as LYL797, LYL119, and LYL845, all designed to deliver improved and potentially curative outcomes for patients suffering from solid tumors.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Omniome, Inc. is a biotechnology company based in San Diego, California, that specializes in developing a proprietary DNA sequencing platform aimed at providing high accuracy in clinical sequencing. Founded in 2013, Omniome utilizes its Sequencing By Binding technology to enhance nucleotide and DNA matching, leveraging the natural matching capabilities of polymerases. This innovative approach allows researchers to achieve accurate and rapid sequencing results while maintaining low costs. The company's ambition is to become a leading name in DNA sequencing, particularly in advancing cancer diagnostics and improving outcomes in clinical settings.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Nohla Therapeutics, Inc., established in 2015 and headquartered in Seattle, Washington, specializes in developing and manufacturing ex vivo expanded universal donor cellular therapies. The company's core technology enables the expansion of key cancer-fighting cells from umbilical cord blood, eliminating the need for HLA matching. Nohla offers programs such as Natural Killer (NK) cell therapy and Dilanubicel, a universal donor hematopoietic stem and progenitor cell product used for treating chemotherapy-induced neutropenia and other indications. Its products are manufactured and cryopreserved in advance, ensuring immediate availability for patient treatment.

AgBiome is a biotechnology company that develops biological products for agriculture by leveraging the plant-associated microbiome. It identifies plant microbes with potential to improve plant health, pest resistance, and yields, using genomics and screening technologies. The company builds a microbial collection and operates a platform to discover ingredients for agriculturally relevant applications, including fungicides and other biologics that target soil-borne diseases, insects, and nematodes. Through partnerships with agricultural players, AgBiome accelerates discovery and global deployment of solutions. It is based in Durham, North Carolina, with a state-of-the-art laboratory and greenhouse facility, and has a substantial research team.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.